Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.54 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 4/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11260997 | 0.88 | CYP3A4 (0.48) | CYP3A4CYP2C9PDGFRAMAPK1MAPKAPK2 | |
| SCHEMBL28568153 | 0.84 | SYK (0.52) | CYP3A4CYP2C9PDGFRAMAPK1MAPKAPK2 | |
| SCHEMBL2483519 | 0.83 | FPR2 (0.49) | MAPK1POLBMAPTKDM4EALDH1A1 | |
| SCHEMBL2483521 | 0.83 | FPR2 (0.49) | MAPK1POLBMAPTKDM4EALDH1A1 | |
| SCHEMBL146704 | 0.83 | FPR2 (0.49) | MAPK1POLBMAPTKDM4EALDH1A1 | |
| SCHEMBL16838610 | 0.83 | MAPT (0.50) | CYP3A4CYP2C9PDGFRAMAPK1MAPKAPK2 | |
| SCHEMBL28534876 | 0.82 | FPR2 (0.47) | MAPK1KMT2AGAAGFERPOLB | |
| SCHEMBL23715809 | 0.81 | NPC1 (0.50) | CYP3A4CYP2C9PDGFRAMAPK1MAPKAPK2 | |
| SCHEMBL23716088 | 0.80 | ALDH1A1 (0.47) | CYP3A4CYP2C9PDGFRAMAPK1MAPKAPK2 | |
| SCHEMBL3839169 | 0.80 | ALDH1A1 (0.47) | CYP3A4CYP2C9PDGFRAMAPK1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1200097-B1 | METHOD FOR CONTROLLING THE FIDELITY AND THE PROCESSIVITY OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION | VIGILENT TECHNOLOGIES (FR) | 2014-01-08 | — | — | EP | claimed |
| US-6925388-B1 | Heterocyclic nonnucleoside inhibitors of reverse transcriptase | PARKER HUGHES INSTITUTE (US) | 2005-08-02 | — | — | US | claimed |
| US-6727059-B1 | ADMINISTERING A NUCLEOSIDE ANALOG THAT HAS A 3' HYDROXYL GROUP LOCATED ON THE C3' CARBON OF THE 2'-DEOXYRIBOSE, FOR EXAMPLE DUTP; FOR RETROID VIRUS INFECTIONS SUCH AS HIV; MIXTURE WITH REVERSE TRANSCRIPTASE INHIBITORS SUCH AS AZT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-04-27 | — | — | US | claimed |
| WO-2003082777-A2 | NOVEL GLUCOCORTICOID RECEPTOR LIGANDS | KARO BIO AB (SE) | 2003-10-09 | — | — | WO | claimed |
| WO-2003075010-A2 | NON-PEPTIDE IMMUNOLOGIC TRACER PRECURSORS COMPRISING A TYROSYL-(X)N OR LYSINE-(X)N TYROSINE MOTIF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS- (FR) | 2003-09-12 | — | — | WO | claimed |
| EP-1200097-A2 | METHOD FOR CONTROLLING THE FIDELITY AND THE EXECUTION OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION | Vigilent Technologies (FR) | 2002-05-02 | — | — | EP | claimed |
| WO-2000067698-A2 | METHOD FOR CONTROLLING THE FIDELITY AND EXECUTION OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTABLE AS SUBSTRATES WITHOUT BLOCKING ITS ELONGATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2000-11-16 | — | — | WO | claimed |
| WO-1997016543-A9 | STRUCTURE BASED DESIGN OF INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | — | 1997-07-24 | — | — | WO | claimed |
| WO-1997016543-A1 | STRUCTURE BASED DESIGN OF INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY (US) | 1997-05-09 | — | — | WO | claimed |
| CN-101031550-B | HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines | TIBOTEC PHARM LTD | 2015-05-27 | — | — | CN | disclosed |
| CN-101816658-B | HIV inhibiting pyrimidines derivatives | JANSSEN PHARMACEUTICA NV | 2014-08-27 | — | — | CN | disclosed |
| EP-1200097-B1 | METHOD FOR CONTROLLING THE FIDELITY AND THE PROCESSIVITY OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION | VIGILENT TECHNOLOGIES (FR) | 2014-01-08 | — | — | EP | disclosed |
| CN-1668305-B | Microbicidal pyrimidines or triazines for the prevention of sexual transmission of HIV | TIBOTEC PHARM LTD | 2013-06-12 | — | — | CN | disclosed |
| US-8044091-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| WO-1997005864-A2 | USE OF L-CARNITINE AND DERIVATIVES FOR REDUCING CERAMIDE LEVELS AND POTENTIATING ANTIRETROVIRAL DRUGS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1997-02-20 | — | — | WO | disclosed |
| WO-1996016675-A2 | COMPOSITION FOR PREVENTION AND TREATMENT OF HIV-1 INFECTION COMPRISING AT LEAST TWO DIFFERENT HIV-1 REVERSE TRANSCRIPTASE INHIBITORS | REGA INSTITUTE (BE) | 1996-06-06 | — | — | WO | disclosed |
| CN-1118137-A | Method of reversing zidovudine resistance of HIV-1 strains | JANSSEN PHARMACEUTICA NV (BE) | 1996-03-06 | — | — | CN | disclosed |
| WO-1996000068-A2 | COMBINATION THERAPY FOR HIV INFECTION | MERCK & CO., INC. (US) | 1996-01-04 | — | — | WO | disclosed |
| EP-0639971-A1 | THERAPEUTIC COMBINATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023021-A2 | THERAPEUTIC COMBINATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-11-25 | — | — | WO | disclosed |